Docetaxel for the treatment of breast cancer -a highly efficient agent with moderate side effects;Docetaxel (Taxotere®) zur Therapie des Mammakarzinoms Höchste Wirksamkeit bei moderaten Nebenwirkungen

Medizinische Klinik

Volumn 92, Issue SUPPL. 4, 1997, Pages 4-9

  Von Minckwitz, Gunter ^a   Costa, Serban Dan ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Anthracyclins urban vogel; Breast cancer; Docetaxel

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DOCETAXEL; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; DRUG POTENTIATION; FEMALE; HUMAN; LIVER TUMOR; METASTASIS; MORTALITY; PATHOLOGY; REVIEW; SURVIVAL RATE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DRUG SYNERGISM; FEMALE; HUMANS; LIVER NEOPLASMS; PACLITAXEL; SURVIVAL RATE; TAXOIDS;

EID: 0031571687     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03041969     Document Type: Article

References (16)

1. Bozec, I., J. M. Nûbhohz, V. Dieris ci a!.: Doceuxd (D) in combination with doxorubicin (Dx) (AT) and with cyclophosphaniidL' (CTX) (TAC) as first-line chemotherapy (CT) in metaatic breast cancer (MI3C): high activir>- and absence ofcarjiotoxicity. Proc. ASCO 16 (1997), 566.
2. Chan, S., K. Friedrichs, D. Noel, R. Duarte et al.: A randomized phase IM study of Taxotere (T) venus Doxorubicin (D) in patients (pts) with metastatic breast cancer (MDC) who have failed an alkylaring containing regimen: preliminary results. Proc. ASCO 16 (19'/7), 540.
3. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 2-1000 deaths among 75 women. Lancet 339 (1992), 1-15,71-85.
4. Extra, J. M., F. Rousseau, R. Bruno et al.: Phase I and phannacokinctic study of taxotere (RP 56976, NSC 62S503) given as a short intravenous infusion. Cancer Res. 53(1993), 1037-1042.
5. Gianni, L., E. Munzone, G. Capri, F, Fultaro, E. Tarenzi, F. Vilhni, C. Spreafico, A. Latlranchi, A. Caraceni, C. Martini et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high amitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. clin. Oncol. 13 (1995). 2688-2699.
6. Honig. S. F.: Hormonal therapy and chemotherapy. In: Harris, J. R., M. E. Lippnunn, M. Morrow, S. Hellmann (eds.): Diseases of the breast. Lippincott-Raven, Philadelphia-New York 1996, p. 692-693.
7. T.Jones, S., E. \Viner, C. Vogel, L. Laufman, L. Hutchins, M. O'Rourke, B. Lembersky. D. Budman.J. Bigley.J. Hohneker: Randomized comparison of vinorelbine and melphuhn in anthracycline-refractory advanced breast cancer. J. clin. Oncol. 13 (1995), 2567-2574.
8. Kaufmann, M., G. von Minckwitz: Das primäre Mammakarzinom. Vorschlage und aktuelle Aspekte zur adjuvanren s>-stemischen Therapie. Dt. Ärztebl. 93 (l996), 755-758.
9. Minck\vitz, G. von, S. D. Costa, M. C. Camina Ja, S. Loibl, M. Kaufmann: Combination of doceuxel (D) and mitoxantrone (M) for the treatment of advanced or meustatic breast cancer -a dose-finding study. San Antonio Breast Cancer Meeting 1997 (submitted).
10. Nabholtz,J. M., B. fhuerlimann, \V. R. Bezwoda, D. Melnychuk, M. Alakl, M. Murawsky, A. Riva: Taxocere (T) versus mitomycin C + vinblastine (MV) in patients (pts) with nietastatic breast cancer (M BC) who have failed an anthracycline containing regimen: preliminary results ofa randomized phase III study. Proc. ASCO 16 (1997), 519.
11. .Piccart, M.J..J. Klijn, R. Pandaens et al.: Steroids do reduce the severity and delay the onset ofdocetaxel (DXT) induced fluid retention. Final results of a randomised trial of the EORTC Investi gational Drug Branch for Breast Cancer (1DB13C). Europ.J. Cancer31-A,Suppl. 5 (1995), S175.
12. Ringel, !.. S. B. Horowitz: Studies with RP 56976 (Taxotere): a semisynthetic analog of TaxoI.J. nat. Cancer Inst. (1991), 288-291.
13. Seidman. A. D., A. Tien-ten, C. Hudis, M. Gollub, S. Harrett, T. J. YaoJ. Lepore, T. Gilewski, V. Curne, J. Crown: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for nietastatic breast cancer. J. clin, Oncol. 13 (1995), 2575-2581.
14. Taxotere. Internationale Produkt-Monographie. RhônePoulenc Rorer, Köln 1996, S. 59.
15. Van Oosterom, A. T., D. Schriivers: Docetaxel (Taxocere): a review ofpreclmical and clinical experience. Pan II: Clinical experience. Anticancer Drugs 6 (1995), 356-368.
16. Vermerken, J. B., \V. \V. ten Bokkel Huinink, I. A. M. Mandjes, T.J. Postma, M. T. Huizing.J.J. Heimans.J. H. Beijnen, F. Bierhorst, B. \Vinograd, H. M. Pinedo: Highdose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracyc h ne therapy: a European cancer center trial. Semin. Oncol. 22, Suppl. 8 (1995), 16-22.